Sort   by:  
 Page size 
MetabolomicsAberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma (Xenograft assays)

Glioblastoma (GBM) is a common and deadly form of brain tumor in adults. Dysregulated metabolism in GBM offers an opportunity to deploy metabolic interventions as precise therapeutic strategies. To identify the molecular drivers and the modalities by which different molecular subgroups of GBM exp...

2022-11-08 | MTBLS730 | MetaboLights
MetabolomicsAberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma (Stem cell and cell line assays)

Glioblastoma (GBM) is a common and deadly form of brain tumor in adults. Dysregulated metabolism in GBM offers an opportunity to deploy metabolic interventions as precise therapeutic strategies. To identify the molecular drivers and the modalities by which different molecular subgroups of GBM exp...

2022-11-08 | MTBLS4708 | MetaboLights
ProteomicsA “Two birds One Stone” Strategy for Site-specific Analysis of the Core Fucosylation and O-GlcNAcylation
Core fucosylation and O-GlcNAcylation are two most famous protein glycosylations and regulate diverse physiological and pathological processes in living organism. Core fucosylation is a protein glycosylation in which a L-fucose residue attaches to the innermost N-acetylglucosamine (GlcNAc) of N-glyc...
ORGANISM(S): Homo Sapiens 
2023-12-04 | PXD047486 |
ProteomicsUnbiased quantification of core-fucosylation stoichiometry reveals its role in cancer progression and embryonic development
Core fucosylation on N-glycosylation plays pivotal roles in regulating ligand binding and cell adhesion, and it is critical to investigate the level of core fucosylation changes in biological processes to further understand its functions. Nevertheless, an unbiased method to globally measure the core...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-01-26 | MSV000093936 | MassIVE
ProteomicsGlycoproteomics of healthy and Fut8-KO mice platelet lysates
To validate the knockout of FUT8, the core fucosylation enzyme on mice platelets
ORGANISM(S): Mus musculus (Mouse) 
2026-06-04 | PXD064579 | Pride
Glycoproteomics Fut8 Glycopeptide Blood Lysate Core fucosylation Platelet 
ProteomicsCore fucosylation in mesenchymal glioblastoma
Glycoproteomic screening indicates that core fucosylation activation is more highly enhancedin mesenchymal (MES) than in proneural (PN) glioblastoma cancer stem cells (GSCs) and this pattern is retained in subgroup-specific xenograftsand human patients’ samples. Most MES-restricted core fucosylated ...
ORGANISM(S): Homo sapiens (Human) 
2022-11-09 | PXD033408 | Pride
Glioblastoma Glycoproteomics Cancer stem cells Mass spectrometry 
ProteomicsProteomic identification of the proteins that co-precipitated with FUT8
Essential roles of FUT8 SH3 domain in core fucosylation
ORGANISM(S): Homo Sapiens (human) 
2020-04-29 | PXD018032 | JPOST Repository
ProteomicsA Sensitive and Reversible Labeling Strategy Enables Global Mapping of the Core-Fucosylated Glycoproteome on Cell Surfaces
Core fucosylation, the attachment of α1,6-fucose to the innermost GlcNAc residue of N-glycans, is a unique protein glycosylation in living organisms. It plays significant roles in diverse physiological and pathological processes, and its upregulation has been observed in many cancers. Core fucosylat...
ORGANISM(S): Homo Sapiens 
2022-08-13 | PXD036051 |
ProteomicsWidespread multi-targeted therapy resistance via drug-induced secretome fucosylation
Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted the...
ORGANISM(S): Homo sapiens (Human) 
2023-04-05 | PXD022240 | Pride
N-linked glycosylation Resistance Fucosylation Targeted therapy Secretome 
GenomicsAberrant L-Fucose accumulation and increased core fucosylation are specific metabolic liabilities in mesenchymal glioblastoma
Aberrant L-Fucose accumulation and increased core fucosylation are specific metabolic liabilities in mesenchymal glioblastoma
PRJNA834980 | ENA
Sort   by:  
 Page size